Bulk Manufacturer of Controlled Substances Application: Sterling Pharma USA, LLC, 76083-76084 [2022-26913]
Download as PDF
<![CDATA[
76083
Federal Register / Vol. 87, No. 237 / Monday, December 12, 2022 / Notices
lotter on DSK11XQN23PROD with NOTICES1
those States’ decisions on whether to
participate in neither, one, or both relief
options for calendar year 2023. An ‘‘N/
A’’ means that no properties within the
State met that condition for that type of
relief:
State
Cumulative
royalty report and
payment relief
(less than 1,000
BOE per year)
Alabama ...........................................................................................................................................
Arkansas ..........................................................................................................................................
California ..........................................................................................................................................
Colorado ..........................................................................................................................................
Kansas .............................................................................................................................................
Louisiana ..........................................................................................................................................
Michigan ...........................................................................................................................................
Montana ...........................................................................................................................................
Nebraska ..........................................................................................................................................
Nevada .............................................................................................................................................
New Mexico .....................................................................................................................................
North Dakota ....................................................................................................................................
Oklahoma .........................................................................................................................................
South Dakota ...................................................................................................................................
Utah .................................................................................................................................................
Wyoming ..........................................................................................................................................
NO .............................
N/A ............................
NO .............................
NO .............................
NO .............................
YES ...........................
NO .............................
NO .............................
NO .............................
N/A ............................
NO .............................
YES ...........................
NO .............................
YES ...........................
NO .............................
YES ...........................
Pursuant to 30 U.S.C. 1726(c), a
Federal oil and gas property located in
a State where ONRR does not share a
portion of Federal royalties with that
State (that is, for 2024, a State not listed
in the table above) is eligible for relief
if it qualifies as a marginal property. For
more information on how to obtain
relief, please refer to 30 CFR 1204.205.
Unless the information that ONRR
receives is proprietary data, all
correspondence, records, or information
received in response to this Notice may
be subject to disclosure under the
Freedom of Information Act (FOIA, 5
U.S.C. 552 et seq.). If applicable, please
highlight the proprietary portions,
including any supporting
documentation, or mark the page(s)
containing proprietary data. ONRR
protects proprietary information under
the Trade Secrets Act (18 U.S.C. 1905),
FOIA Exemption 4 (5 U.S.C. 552(b)(4)),
and the Department of the Interior’s
FOIA regulations (43 CFR part 2).
Authority: Federal Oil and Gas
Royalty Management Act of 1982, 30
U.S.C. 1701 et seq., as amended by
Federal Oil and Gas Royalty
Simplification and Fairness Act of 1996
(RSFA, Pub. L. 104–185—Aug. 13, 1996,
as corrected by Pub. L. 104–200—Sept.
22, 1996).
INTERNATIONAL TRADE
COMMISSION
Issued: December 7, 2022.
Katherine Hiner,
Acting Secretary to the Commission.
[USITC SE–22–055]
[FR Doc. 2022–26965 Filed 12–8–22; 11:15 am]
Howard M. Cantor,
Acting Director, Office of Natural Resources
Revenue.
[FR Doc. 2022–26918 Filed 12–9–22; 8:45 am]
BILLING CODE 4335–30–P
18:08 Dec 09, 2022
Jkt 259001
NO.
YES.
NO.
NO.
NO.
YES.
YES.
NO.
NO.
YES.
YES.
YES.
NO.
YES.
NO.
NO.
BILLING CODE 7020–02–P
Sunshine Act Meetings
United
States International Trade Commission.
AGENCY HOLDING THE MEETING:
TIME AND DATE:
December 19, 2022 at
11:00 a.m.
STATUS:
Open to the public.
1. Agendas for future meetings: none.
2. Minutes.
3. Ratification List.
4. Commission vote on Inv. Nos. 731–
TA–1587–1590 (Final)(Certain
Preserved Mushrooms from France,
Netherlands, Poland, and Spain). The
Commission currently is scheduled to
complete and file its determinations and
views of the Commission on January 5,
2023.
5. Outstanding action jackets: none.
CONTACT PERSON FOR MORE INFORMATION:
Tyrell Burch, Management Analyst,
202–205–2595.
The Commission is holding the
meeting under the Government in the
Sunshine Act, 5 U.S.C. 552(b). In
accordance with Commission policy,
subject matter listed above, not disposed
of at the scheduled meeting, may be
carried over to the agenda of the
following meeting.
Frm 00060
Drug Enforcement Administration
Fmt 4703
Sfmt 4703
Bulk Manufacturer of Controlled
Substances Application: Sterling
Pharma USA, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
MATTERS TO BE CONSIDERED:
PO 00000
DEPARTMENT OF JUSTICE
[Docket No. DEA–1112]
Room 101, 500 E Street SW,
Washington, DC 20436, Telephone:
(202) 205–2000.
PLACE:
By order of the Commission:
VerDate Sep<11>2014
Other accounting
and auditing relief
(less than 15 BOE
per well per day)
Sterling Pharma USA, LLC
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before February 10, 2023. Such
persons may also file a written request
for a hearing on the application on or
before February 10, 2023.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
SUMMARY:
E:\FR\FM\12DEN1.SGM
12DEN1
76084
Federal Register / Vol. 87, No. 237 / Monday, December 12, 2022 / Notices
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on October 7, 2022,
Sterling Pharma USA, LLC, 1001
Sheldon Drive, Suite 101, Cary, North
Carolina 27513–2078, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
Controlled substance
5-Methoxy-N-Ndimethyltryptamine.
Psilocybin ........................
Psilocyn ...........................
Drug
code
Schedule
7431
I
7437
7438
I
I
The company plans to manufacture
the above-listed controlled substances
as clinical trials. No other activities for
these drug codes are authorized for this
registration.
Matthew Strait,
Deputy Assistant Administrator.
Drug
code
Controlled substance
[FR Doc. 2022–26913 Filed 12–9–22; 8:45 am]
Psilocybin .....................
Psilocyn ........................
BILLING CODE P
Drug Enforcement Administration
[Docket No. DEA–1119]
Bulk Manufacturer of Controlled
Substances Application: Scottsdale
Research Institute
7437
7438
I
II
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2022–26922 Filed 12–9–22; 8:45 am]
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
BILLING CODE P
Scottsdale Research Institute
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
SUMMARY:
I
Schedule
The company plans to bulk
manufacture the listed controlled
substances for internal research
purposes and to support clinical trials.
No other activities for these drug codes
are authorized for this registration.
DEPARTMENT OF JUSTICE
lotter on DSK11XQN23PROD with NOTICES1
the issuance of the proposed registration
on or before February 10, 2023. Such
persons may also file a written request
for a hearing on the application on or
before February 10, 2023.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on September 28, 2022,
Scottsdale Research Institute, 12815
North Cave Creek Road, Phoenix,
Arizona 85022, applied to be registered
as a bulk manufacturer of the following
basic class(es) of controlled
substance(s):
DEPARTMENT OF JUSTICE
ACTION:
Notice of application.
VHG Labs dba LGC Standards
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before January 11, 2023. Such
persons may also file a written request
for a hearing on the application on or
before January 11, 2023.
DATES:
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
ADDRESSES:
In
accordance with 21 CFR 1301.34(a), this
is notice that on September 12, 2022,
VHG Labs dba LGC Standards, 3
Perimeter Road, Manchester, New
Hampshire 03103–3341, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Drug Enforcement Administration
[Docket No. DEA–1114]
Importer of Controlled Substances
Application: VHG Labs dba LGC
Standards
Drug Enforcement
Administration, Justice.
AGENCY:
Controlled substance
Drug code
Cathinone ........................................................................................................................................................................
Methcathinone .................................................................................................................................................................
VerDate Sep<11>2014
18:08 Dec 09, 2022
Jkt 259001
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
E:\FR\FM\12DEN1.SGM
12DEN1
1235
1237
Schedule
I
I
]]>Agencies
[Federal Register Volume 87, Number 237 (Monday, December 12, 2022)]
[Notices]
[Pages 76083-76084]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-26913]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1112]
Bulk Manufacturer of Controlled Substances Application: Sterling
Pharma USA, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Sterling Pharma USA, LLC has applied to be registered as a
bulk manufacturer of basic class(es) of controlled substance(s). Refer
to SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
February 10, 2023. Such persons may also file a written request for a
hearing on the application on or before February 10, 2023.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to
[[Page 76084]]
https://www.regulations.gov and follow the online instructions at that
site for submitting comments. Upon submission of your comment, you will
receive a Comment Tracking Number. Please be aware that submitted
comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number,
your comment has been successfully submitted and there is no need to
resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on October 7, 2022, Sterling Pharma USA, LLC, 1001
Sheldon Drive, Suite 101, Cary, North Carolina 27513-2078, applied to
be registered as a bulk manufacturer of the following basic class(es)
of controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
5-Methoxy-N-N-dimethyltryptamine........ 7431 I
Psilocybin.............................. 7437 I
Psilocyn................................ 7438 I
------------------------------------------------------------------------
The company plans to manufacture the above-listed controlled
substances as clinical trials. No other activities for these drug codes
are authorized for this registration.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2022-26913 Filed 12-9-22; 8:45 am]
BILLING CODE P
